Lisly Chery
Department of Urology, Division of Surgery
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Urology, Division of Surgery Division, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2009 | Albert Einstein College of Medicine, Bronx, New York, US, MD |
| 2003 | Princeton University, New Jersey, New Jersey, US, Molecular Biology, BA |
Postgraduate Training
| 2015-2017 | Clinical Fellowship, Urologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2014-2015 | Chief Residency, University of Washington, Seattle, Washington |
| 2010-2014 | Clinical Residency, Urology, University of Washington, Seattle, Washington |
| 2009-2010 | Clinical Internship, General Surgery, University of Washington, Seattle, Washington |
Licenses & Certifications
| 2009 | Texas Medical Board |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2024
Other Professional Positions
Consulting Physician, Harris County Sheriff's Office, Houston, TX, 2017
Clinical Specialist, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2017
Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2017
Urology Resident, University of Washington School of Medicine, Seattle, WA, 2009 - 2015
Academic Tutor, Albert Einstein College of Medicine, Bronx, NY, 2006 - 2007
Peer Assistant, Albert Einstein College of Medicine, Bronx, NY, 2006 - 2007
Counselor, Prep for Prep, Bronx, NY, 2003 - 2004
Honors & Awards
| 2016 | Best Poster Award, American Urological Association |
| 2016 | National Medical Association Travel Award, National Institute of Health |
| 2014 | Resident as Teacher Award, University of Washington |
| 2013 - 2016 | Urology In-Service Award, University of Washington |
| 2013 | R. Frank Jones Urological Society Residents Excellence in Research, R. Frank Jones Urological Society |
| 2013 | Resident Travel Award for Underrepresented Populations, American Society of Clinical Oncology |
| 2012 | SNMA Travel Award, Office of GME and the Center for Diversity, Equity and Inclusion |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2016. The Risk of Chronic Kidney Disease in the Elderly After Radical or Partial Nephrectomy for Masses Larger Than pT1a. Conference. AUA Annual Meeting. San Diego, CA, US.
- 2014. PTEN loss in Localized Prostate Cancer: Clinicopathologic Parameters and Relationship with Disease Outcome. Conference. AUA Annual Meeting. Orlando, FL, US.
- 2013. Aspirin Use Reduces the Risk of TMPRSS2:ERG Positive Prostate Cancer. Podium Presentation. Conference. AUA Annual Meeting. San Diego, CA, US.
- 2013. Prostate Cancer Disseminated Timor Cell Heterogeneity and Dormancy. Poster Presentation. Conference. AUA Annual Meeting. San Diego, CA, US.
- 2012. Salvage Radiation for Recurrent Prostate Cancer in a Veteran’s Administration Population. Abstract presentation. Conference. Northwest Urological Society. Seattle, WA, US.
- 2012. NSAIDs and statin use and risk of renal cell carcinoma. Poster presentation. Conference. AUA Annual Meeting. Atlanta, GA, US.
International Presentations
- 2013. Aspirin Use Reduces the Risk of TMPRSS2:ERG Positive Prostate Cancer. Podium Presentation. Conference. National Medical Association Annual Meeting. Toronto, CA.
Selected Publications
Peer-Reviewed Articles
- Gregg, JR, Newcomb, LF, Wu, R, Dennison, JB, Davis, JW, Pettaway, CA, Pisters, L, Ward, JF, Chapin, BF, Chery, LJ, Urkmez, A, Fang, A, Higgason, N, Troncoso, P, Daniel-MacDougall, CR, Logothetis, CJ, Thompson, TC, Hahn, AW, Liu, M, Zheng, Y, Lin, DW, Hanash, SM, Irajizad, E, Fahrmann, JF. Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance. Biomarker Research 12(1), 2024. e-Pub 2024. PMID: 39522029.
- Hahn, AW, Manyam, GC, Chapin, BF, Zhang, M, Yu, Y, Pettaway, CA, Chery, LJ, Pisters, LL, Ward, JF, Gregg, JR, Papadopoulos, JN, Kamat, A, Lozano, M, Hoang, A, Broom, BM, Wang, X, Huff, C, Logothetis, CJ, Troncoso, P, Pilie, PG, Davis, JW. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU international 134(3):449-458, 2024. e-Pub 2024. PMID: 38837608.
- Gu, J, Chery, LJ, González, GM, Huff, C, Strom, SS, Jones, J, Griffith, DP, Canfield, SE, Wang, X, Huang, X, Roberson, P, Meng, QH, Troncoso, P, Ittmann, MM, Covinsky, MH, Scheurer, ME, Irizarry-Ramírez, M, Pettaway, CA. A west African ancestry-associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening. Prostate 84(7):694-705, 2024. e-Pub 2024. PMID: 38477020.
- Gregg, JR, Magill, RG, Fang, AM, Chapin, BF, Davis, JW, Adibi, M, Chery, LJ, Papadopoulos, JN, Pettaway, CA, Pisters, LL, Ward, J, Hahn, AW, Daniel-MacDougall, CR, Bhaskaran, J, Zhu, K, Guerrero, M, Zhang, M, Troncoso, P. The association of body mass index with tumor aggression among men undergoing radical prostatectomy. Urologic Oncology: Seminars and Original Investigations 42(4):116.e1-116.e7, 2024. e-Pub 2024. PMID: 38262868.
- Labbate, CV, Hensley, PJ, Miest, T, Qiao, W, Adibi, M, Shah, AY, Chery, LJ, Papadopoulos, JN, Siefker-Radtke, AO, Gao, J, Guo, CC, Czerniak, BA, Navai, N, Kamat, A, Dinney, CP, Campbell, M, Matin, S. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations 40(10):454.e17-454.e23, 2022. e-Pub 2022. PMID: 35961847.
- Westerman, ME, Bree, KK, Msaouel, P, Kukreja, JB, Mantaring, C, Rukundo, I, Gonzalez, MG, Gregg, JR, Casteel, KN, Matin, S, Lafleur, AD, Best, RN, Crump, LD, Cunningham, JM, Saucedo, MA, Valle, DD, Varghese, R, Adibi, M, Chapin, BF, Chery, LJ, Davis, JW, Dinney, CP, Graber, WJ, Kamat, A, Karam, JA, Navai, N, Papadopoulos, JN, Pettaway, CA, Pisters, LL, Smith III, T, Ward, JF, Westney, OL, Wood, CG. Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis. Journal of Urology 208(4):886-895, 2022. e-Pub 2022. PMID: 36082549.
- Borregales, LD, Adibi, M, Thomas, AZ, dos Reis, RB, Chery, LJ, Devine, CE, Wang, X, Potretzke, AM, Potretzke, T, Figenshau, RS, Bauman, TM, Aboshady, YI, Abel, EJ, Matin, S, Karam, JA, Wood, CG. Predicting Adherent Perinephric Fat Using Preoperative Clinical and Radiological Factors in Patients Undergoing Partial Nephrectomy. European Urology Focus 7(2):397-403, 2021. e-Pub 2021. PMID: 31685445.
- Bitar, RD, Szklaruk, J, Martiniova, L, Zurita-Saavedra, A, Chery, LJ, Ravizzini, G. 18F-Fluciclovine Uptake in a Ureterocele. Clinical nuclear medicine 46(1):E3-E5, 2021. e-Pub 2021. PMID: 32956112.
- Chéry L, Borregales LD, Fellman B, Urbauer DL, Garg N, Parker N, Katz MHG, Wood CG, Karam JA. The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma. Urology 108:114-121, 2017. e-Pub 2017. PMID: 28705573.
- Roudier MP, Winters BR, Coleman I, Lam HM, Zhang X, Coleman R, Chéry L, True LD, Higano CS, Montgomery B, Lange PH, Snyder LA, Srivastava S, Corey E, Vessella RL, Nelson PS, Üren A, Morrissey C. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer. Prostate 76(9):810-22, 2016. e-Pub 2016. PMID: 26990456.
- Wright JL, Chéry L, Holt S, Lin DW, Luedeke M, Rinckleb AE, Maier C, Stanford JL. Aspirin and NSAID use in association with molecular subtypes of prostate cancer defined by TMPRSS2:ERG fusion status. Prostate Cancer Prostatic Dis 19(1):53-6, 2016. e-Pub 2016. PMID: 26503111.
- Figler BD, Chery L, Friedrich JB, Wessells H, Voelzke BB. Limited Panniculectomy for Adult Buried Penis Repair. Plast Reconstr Surg 136(5):1090-2, 2015. e-Pub 2015. PMID: 26182174.
- Zhang X, Coleman IM, Brown LG, True LD, Kollath L, Lucas JM, Lam HM, Dumpit R, Corey E, Chéry L, Lakely B, Higano CS, Montgomery B, Roudier M, Lange PH, Nelson PS, Vessella RL, Morrissey C. SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer. Clin Cancer Res 21(20):4698-708, 2015. e-Pub 2015. PMID: 26071481.
- Macleod LC, Chery LJ, Hu EY, Zeliadt SB, Holt SK, Lin DW, Porter MP, Gore JL, Wright JL. Metabolic syndrome, dyslipidemia and prostate cancer recurrence after primary surgery or radiation in a veterans cohort. Prostate Cancer Prostatic Dis 18(2):190-5, 2015. e-Pub 2015. PMID: 25823651.
- Chéry L, Lam HM, Coleman I, Lakely B, Coleman R, Larson S, Aguirre-Ghiso JA, Xia J, Gulati R, Nelson PS, Montgomery B, Lange P, Snyder LA, Vessella RL, Morrissey C. Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. Oncotarget 5(20):9939-51, 2014. e-Pub 2014. PMID: 25301725.
- Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chéry L, Siddiqui J, Nelson PS, Vessella RL, Knudsen BS, Chinnaiyan AM, Pienta KJ, Morrissey C, Tewari M. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One 8(7):e69239, 2013. e-Pub 2013. PMID: 23935962.
- Hakimi AA, Rajpathak S, Chery L, Shapiro E, Ghavamian R. Renal insufficiency is an independent risk factor for complications after partial nephrectomy. J Urol 183(1):43-7, 2010. e-Pub 2010. PMID: 19913240.
Review Articles
- Fang, A, Frigo, DE, Hahn, AW, Razouki, ZA, Hwang, J, Koutroumpakis, E, Lawen, T, Smith, MR, Hamilton-Reeves, J, DiGiovanni, J, Higgason, N, Garcia, RS, Chapin, BF, Pettaway, CA, Chery, LJ, Troncoso, P, Logothetis, CJ, Daniel-MacDougall, CR, Wei, P, Gregg, JR. GLP-1 Agonist Use Among Men With Localized Prostate Cancer. Urology 201:152-158, 2025. e-Pub 2025. PMID: 40348027.
- Fang, A, Jackson, J, Gregg, JR, Chery, LJ, Tang, C, Surasi, DS, Siddiqui, BA, Soroush-Rais-Bahrami, Bathala, TK, Chapin, BF. Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer. Current treatment options in oncology 25(1):66-83, 2024. e-Pub 2024. PMID: 38212510.
- McCormick, B, Chery, LJ, Chapin, BF. Contemporary outcomes following robotic prostatectomy for locally advanced and metastatic prostate cancer. Translational Andrology and Urology 10(5):2178-2187, 2021. e-Pub 2021. PMID: 34159100.
- Chery LJ, Karam JA, Wood CG. Cytoreductive nephrectomy for metastatic renal cell carcinoma. Clin Adv Hematol Oncol 14(9):696-703, 2016. e-Pub 2016. PMID: 27673288.
- Chéry L, Dash A. The Role of Postchemotherapy Surgery in Germ Cell Tumors. Urol Clin North Am 42(3):331-42, 2015. e-Pub 2015. PMID: 26216820.
Other Articles
- Fang, A, Jackson, J, Gregg, JR, Chery, LJ, Tang, C, Surasi, DS, Siddiqui, BA, Rais-Bahrami, S, Bathala, TK, Chapin, BF Correction to. Current treatment options in oncology 25(5):617-618, 2024. PMID: 38642282.
Book Chapters
- Kundra, V, Chery, LJ, Hoffman, K. Prostate Cancer, 370-393, 2022.
Patient Reviews
CV information above last modified October 30, 2025